$CUE
Cue Biopharma, Inc.

2023 Q3 Form 10-Q Financial Statement

#000095017023039770 Filed on August 08, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2022 Q2
Revenue $2.100M $1.382M $26.00K
YoY Change 2988.24% 5215.38% -99.05%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.650M $4.249M $3.782M
YoY Change 3.46% 12.35% -11.12%
% of Gross Profit
Research & Development $9.874M $10.65M $9.592M
YoY Change 30.42% 11.03% 9.47%
% of Gross Profit
Depreciation & Amortization $128.0K $132.0K $212.0K
YoY Change -35.35% -37.74% -8.23%
% of Gross Profit
Operating Expenses $13.52M $14.90M $13.12M
YoY Change 21.8% 13.59% 0.57%
Operating Profit -$11.42M -$13.52M -$13.09M
YoY Change 3.52% 3.26% 27.05%
Interest Expense $254.0K $350.0K $206.0K
YoY Change 104.84% 69.9%
% of Operating Profit
Other Income/Expense, Net $414.0K $332.0K -$118.0K
YoY Change 444.74% -381.36% -591.67%
Pretax Income -$11.01M -$13.19M -$13.21M
YoY Change 0.5% -0.17% 28.49%
Income Tax
% Of Pretax Income
Net Earnings -$11.01M -$13.19M -$13.21M
YoY Change 0.46% -0.17% 28.49%
Net Earnings / Revenue -524.05% -954.05% -50800.0%
Basic Earnings Per Share -$0.24 -$0.29 -$0.37
Diluted Earnings Per Share -$0.24 -$0.29 -$373.6K
COMMON SHARES
Basic Shares Outstanding 44.96M 43.18M 35.37M
Diluted Shares Outstanding 46.36M 44.80M 35.36M

Balance Sheet

Concept 2023 Q3 2023 Q2 2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $54.69M $57.89M $66.13M
YoY Change -7.59% -12.46% -10.54%
Cash & Equivalents $54.69M $52.90M $66.13M
Short-Term Investments $0.00 $4.988M $0.00
Other Short-Term Assets $1.200M $1.911M $2.142M
YoY Change -30.27% -10.78% -44.41%
Inventory
Prepaid Expenses
Receivables $1.661M $1.135M $736.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $57.52M $60.94M $69.00M
YoY Change -6.78% -11.69% -13.4%
LONG-TERM ASSETS
Property, Plant & Equipment $1.064M $1.192M $1.765M
YoY Change -35.2% -32.46% -31.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $120.0K $123.0K $134.0K
YoY Change -8.4% -8.21% -95.4%
Total Long-Term Assets $11.37M $12.23M $15.75M
YoY Change -22.12% -22.34% 57.53%
TOTAL ASSETS
Total Short-Term Assets $57.52M $60.94M $69.00M
Total Long-Term Assets $11.37M $12.23M $15.75M
Total Assets $68.89M $73.16M $84.75M
YoY Change -9.71% -13.67% -5.49%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.480M $2.356M $1.568M
YoY Change 21.27% 50.26% -47.59%
Accrued Expenses $5.127M $4.076M $3.559M
YoY Change 32.17% 14.53% -48.25%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due $4.000M $4.000M
YoY Change 300.0%
Total Short-Term Liabilities $17.21M $16.31M $8.323M
YoY Change 68.33% 95.93% -50.08%
LONG-TERM LIABILITIES
Long-Term Debt $5.160M $6.118M $9.913M
YoY Change -42.62% -38.28%
Other Long-Term Liabilities $3.900M $4.734M $6.757M
YoY Change -38.3% -29.94% 7492.13%
Total Long-Term Liabilities $5.160M $6.118M $9.913M
YoY Change -42.62% -38.28% 11038.2%
TOTAL LIABILITIES
Total Short-Term Liabilities $17.21M $16.31M $8.323M
Total Long-Term Liabilities $5.160M $6.118M $9.913M
Total Liabilities $26.22M $27.16M $24.99M
YoY Change 2.69% 8.67% 49.11%
SHAREHOLDERS EQUITY
Retained Earnings -$287.8M -$276.8M -$224.9M
YoY Change 22.0% 23.05%
Common Stock $330.4M $322.8M $284.7M
YoY Change 15.24% 13.38%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $42.67M $46.00M $59.76M
YoY Change
Total Liabilities & Shareholders Equity $68.89M $73.16M $84.75M
YoY Change -9.71% -13.67% -5.49%

Cashflow Statement

Concept 2023 Q3 2023 Q2 2022 Q2
OPERATING ACTIVITIES
Net Income -$11.01M -$13.19M -$13.21M
YoY Change 0.46% -0.17% 28.49%
Depreciation, Depletion And Amortization $128.0K $132.0K $212.0K
YoY Change -35.35% -37.74% -8.23%
Cash From Operating Activities -$7.800M -$10.37M -$12.85M
YoY Change 13.52% -19.28% 31.57%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 -$65.00K
YoY Change -100.0% -100.0% -74.0%
Acquisitions
YoY Change
Other Investing Activities $5.000M $5.000M $3.000K
YoY Change -116.98% 166566.67% -84.21%
Cash From Investing Activities $5.000M $5.000M -$62.00K
YoY Change -116.94% -8164.52% -73.16%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.590M 2.101M 11.11M
YoY Change -51100.0% -81.09% 4.11%
NET CHANGE
Cash From Operating Activities -7.800M -10.37M -12.85M
Cash From Investing Activities 5.000M 5.000M -62.00K
Cash From Financing Activities 4.590M 2.101M 11.11M
Net Change In Cash 1.790M -3.270M -1.801M
YoY Change -104.92% 81.57% -367.21%
FREE CASH FLOW
Cash From Operating Activities -$7.800M -$10.37M -$12.85M
Capital Expenditures $0.00 $0.00 -$65.00K
Free Cash Flow -$7.800M -$10.37M -$12.78M
YoY Change 14.82% -18.87% 34.35%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001645460
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q2 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2022#LicenseMember
us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2022#LicenseMember
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38327
dei Entity Registrant Name
EntityRegistrantName
Cue Biopharma, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-3324577
dei Entity Address Address Line1
EntityAddressAddressLine1
40 Guest Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02135
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
949-2680
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
CUE
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
44959548
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
52901000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
51614000
CY2023Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
4988000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
24675000
CY2023Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1135000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
57000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1911000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
841000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
60935000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
77187000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1192000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1499000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7786000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9203000
CY2023Q2 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
2977000
CY2022Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
3116000
CY2023Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
150000
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
150000
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
123000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
128000
CY2023Q2 us-gaap Assets
Assets
73163000
CY2022Q4 us-gaap Assets
Assets
91283000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2356000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2731000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4076000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3554000
CY2023Q2 cue Research And Development Contract Liability Current
ResearchAndDevelopmentContractLiabilityCurrent
2547000
CY2022Q4 cue Research And Development Contract Liability Current
ResearchAndDevelopmentContractLiabilityCurrent
0
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3365000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3300000
CY2023Q2 us-gaap Other Long Term Debt Current
OtherLongTermDebtCurrent
3963000
CY2022Q4 us-gaap Other Long Term Debt Current
OtherLongTermDebtCurrent
1963000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
16307000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
11548000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4598000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6017000
CY2023Q2 cue Research And Development Contract Liability Net Of Current Portion
ResearchAndDevelopmentContractLiabilityNetOfCurrentPortion
136000
CY2022Q4 cue Research And Development Contract Liability Net Of Current Portion
ResearchAndDevelopmentContractLiabilityNetOfCurrentPortion
0
CY2023Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
6118000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
8035000
CY2023Q2 us-gaap Liabilities
Liabilities
27159000
CY2022Q4 us-gaap Liabilities
Liabilities
25600000
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43744414
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43744414
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43042548
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43042548
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
44000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
43000
CY2023Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
322715000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
316192000
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-5000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-96000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-276750000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-250456000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
46004000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
65683000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
73163000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
91283000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1382000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
26000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1570000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1026000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4249000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3782000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8425000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8938000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10650000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9592000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20041000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19675000
CY2023Q2 cue Gain On Right Of Use Asset Termination
GainOnRightOfUseAssetTermination
0
CY2022Q2 cue Gain On Right Of Use Asset Termination
GainOnRightOfUseAssetTermination
258000
cue Gain On Right Of Use Asset Termination
GainOnRightOfUseAssetTermination
0
cue Gain On Right Of Use Asset Termination
GainOnRightOfUseAssetTermination
258000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
14899000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
13116000
us-gaap Operating Expenses
OperatingExpenses
28466000
us-gaap Operating Expenses
OperatingExpenses
28355000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-13517000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-13090000
us-gaap Operating Income Loss
OperatingIncomeLoss
-26896000
us-gaap Operating Income Loss
OperatingIncomeLoss
-27329000
CY2023Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
564000
CY2022Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
88000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1056000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
96000
CY2023Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-232000
CY2022Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-206000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-454000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-230000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
332000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-118000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
602000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-134000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-13185000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-13208000
us-gaap Net Income Loss
NetIncomeLoss
-26294000
us-gaap Net Income Loss
NetIncomeLoss
-27463000
CY2023Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
34000
CY2022Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
91000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13151000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13208000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-26203000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-27463000
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.29
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.29
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.37
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.37
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.59
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.59
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.81
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.81
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44798760
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44798760
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35357343
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
35357343
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44725875
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44725875
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34005410
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34005410
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
64673000
CY2022Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5982000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2309000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-13208000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
59756000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
55017000
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2016000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2037000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
85000
CY2023Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
34000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-13185000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
46004000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
65492000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
16598000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5320000
cue Restricted Stock Awards Withheld At Vesting To Cover Taxes Amount
RestrictedStockAwardsWithheldAtVestingToCoverTaxesAmount
-191000
us-gaap Net Income Loss
NetIncomeLoss
-27463000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
59756000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
65683000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2016000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4035000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4035000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
473000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
91000
us-gaap Net Income Loss
NetIncomeLoss
-26294000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
46004000
us-gaap Profit Loss
ProfitLoss
-26294000
us-gaap Profit Loss
ProfitLoss
-27463000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
313000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
518000
us-gaap Share Based Compensation
ShareBasedCompensation
4035000
us-gaap Share Based Compensation
ShareBasedCompensation
5320000
cue Change In Operating Lease Right Of Use Asset
ChangeInOperatingLeaseRightOfUseAsset
1416000
cue Change In Operating Lease Right Of Use Asset
ChangeInOperatingLeaseRightOfUseAsset
169000
us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
0
us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
258000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
2000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-4000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
-222000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
18000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
12000
cue Accretion Of Final Payment On Term Loan
AccretionOfFinalPaymentOnTermLoan
65000
cue Accretion Of Final Payment On Term Loan
AccretionOfFinalPaymentOnTermLoan
43000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1077000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2407000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1070000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1268000
cue Increase Decrease In Deposit Liabilities
IncreaseDecreaseInDepositLiabilities
139000
cue Increase Decrease In Deposit Liabilities
IncreaseDecreaseInDepositLiabilities
-1075000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-375000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1023000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
521000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1062000
cue Increase Decrease In Research And Development Contract Liability
IncreaseDecreaseInResearchAndDevelopmentContractLiability
2683000
cue Increase Decrease In Research And Development Contract Liability
IncreaseDecreaseInResearchAndDevelopmentContractLiability
-645000
cue Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-1354000
cue Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-100000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-21204000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-24421000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
92000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
2000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
3000
cue Payments For Redemption Of Short Term Investments
PaymentsForRedemptionOfShortTermInvestments
-20000000
cue Payments For Redemption Of Short Term Investments
PaymentsForRedemptionOfShortTermInvestments
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
20002000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-89000
cue Proceeds From At Time Market Offering Net Of Commission And Fees
ProceedsFromAtTimeMarketOfferingNetOfCommissionAndFees
2016000
cue Proceeds From At Time Market Offering Net Of Commission And Fees
ProceedsFromAtTimeMarketOfferingNetOfCommissionAndFees
16598000
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
0
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
10000000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
473000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
142000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
191000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2489000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
26265000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1287000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1755000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
51764000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
64521000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
53051000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
66276000
us-gaap Interest Paid Net
InterestPaidNet
506000
us-gaap Interest Paid Net
InterestPaidNet
214000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
9057000
cue Operating Lease Modification
OperatingLeaseModification
0
cue Operating Lease Modification
OperatingLeaseModification
7119000
CY2023Q2 us-gaap Marketable Securities
MarketableSecurities
57889000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates include estimates related to collaboration revenue, the accounting for potential liabilities and accrued expenses, the assumptions utilized in valuing stock-based compensation issued for services, the realization of deferred tax assets, and the useful life with respect to long-lived assets and intangibles. Actual results could differ from those estimates.</span></p>
CY2023Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
4993000
CY2023Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2023Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
5000
CY2023Q2 us-gaap Debt Securities Trading And Available For Sale
DebtSecuritiesTradingAndAvailableForSale
4988000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
24771000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
us-gaap Acquired Finite Lived Intangible Assets Weighted Average Useful Life
AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
P15Y
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
96000
CY2022Q4 us-gaap Debt Securities Trading And Available For Sale
DebtSecuritiesTradingAndAvailableForSale
24675000
cue Pre Funded Warrants
PreFundedWarrants
1531440
CY2023Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
4993000
CY2023Q2 us-gaap Debt Securities Held To Maturity Threshold Period Past Due
DebtSecuritiesHeldToMaturityThresholdPeriodPastDue
P12M
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
5000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
24771000
CY2022Q4 us-gaap Debt Securities Held To Maturity Threshold Period Past Due
DebtSecuritiesHeldToMaturityThresholdPeriodPastDue
P12M
CY2022 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
96000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
17824521
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7102379
CY2023Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
52901000
CY2023Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
4988000
CY2022Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
45423000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
24675000
CY2023Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
52901000
CY2023Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
4988000
CY2022Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
45423000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
24675000
CY2023Q2 cue Fair Value Assets Among Level2 And Level3 Transfers Amount
FairValueAssetsAmongLevel2AndLevel3TransfersAmount
0
CY2022Q4 cue Fair Value Assets Among Level2 And Level3 Transfers Amount
FairValueAssetsAmongLevel2AndLevel3TransfersAmount
0
CY2023Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
4988000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
24675000
CY2023Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5699000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5741000
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4507000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4242000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1192000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1499000
CY2023Q2 us-gaap Depreciation
Depreciation
132000
CY2022Q2 us-gaap Depreciation
Depreciation
212000
us-gaap Depreciation
Depreciation
307000
us-gaap Depreciation
Depreciation
432000
cue Amortization Of Trademark
AmortizationOfTrademark
6000
cue Amortization Of Trademark
AmortizationOfTrademark
6000
cue Amortization Of Capitalized License Expense
AmortizationOfCapitalizedLicenseExpense
80000
CY2023Q2 cue Cash Obligation
CashObligation
20000000
CY2023Q2 us-gaap Interest Expense
InterestExpense
350000
CY2022Q2 us-gaap Interest Expense
InterestExpense
33000
CY2023Q2 us-gaap Interest Expense Other
InterestExpenseOther
150000
us-gaap Interest Expense Other
InterestExpenseOther
171000
us-gaap Interest Expense Other
InterestExpenseOther
43000
CY2022Q2 us-gaap Interest Expense Other
InterestExpenseOther
43000
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
2000000
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
4000000
CY2023Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
4000000
CY2023Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
10000000
CY2023Q2 us-gaap Long Term Debt
LongTermDebt
6000000
CY2023Q2 cue Accretion Of Final Payment
AccretionOfFinalPayment
174000
CY2023Q2 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
-55000
CY2023Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
6118000
CY2023Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
4000000
CY2023Q2 us-gaap Deferred Finance Costs Current Gross
DeferredFinanceCostsCurrentGross
37000
CY2023Q2 us-gaap Other Long Term Debt Current
OtherLongTermDebtCurrent
3963000
CY2023Q2 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
141748
CY2023Q2 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
9000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
18000
CY2022Q2 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
9000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
12000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.034
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0399
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.9703
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.038
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0153
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0256
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.921
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.957
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6173867
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.60
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y18D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1461900
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.25
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
165602
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.86
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
365490
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
7.18
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7104675
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.58
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y9M3D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4451956
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
9.70
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y
CY2023Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
10950000
CY2022Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
16175000
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
442000
CY2023Q2 cue Share Based Compensation Arrangement By Share Based Payment Award Fair Value Of Options Exercisable Intrinsic Fair Value Per Share
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfOptionsExercisableIntrinsicFairValuePerShare
9.70
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2037000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2309000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4035000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5320000
cue Number Of Tranches
NumberOfTranches
1
CY2023Q2 us-gaap Warrants And Rights Outstanding Maturity Date
WarrantsAndRightsOutstandingMaturityDate
2015-06-15
cue Pre Funded Warrants
PreFundedWarrants
1531440
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
10719846
cue Class Of Warrants Or Rights Cashless Issue Exercises
ClassOfWarrantsOrRightsCashlessIssueExercises
0
cue Class Of Warrant Or Right Number Of Securities Withheld
ClassOfWarrantOrRightNumberOfSecuritiesWithheld
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
0
CY2023Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
10719846
CY2019Q2 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
2500000
CY2020Q4 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
1250000
CY2021Q4 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
3000000
CY2023Q2 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
134000
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
280000
CY2022Q2 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
128000
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
128000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1666000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
3368000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2799000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
818000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
8651000
CY2023Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
688000
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
7963000
CY2023Q2 cue Operating Leases Rent Expense
OperatingLeasesRentExpense
857000
CY2022Q2 cue Operating Leases Rent Expense
OperatingLeasesRentExpense
1105000
cue Operating Leases Rent Expense
OperatingLeasesRentExpense
1713000
cue Operating Leases Rent Expense
OperatingLeasesRentExpense
2439000
CY2023Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
702000
us-gaap Operating Lease Payments
OperatingLeasePayments
1354000
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
857000
us-gaap Operating Lease Cost
OperatingLeaseCost
1713000
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y9M14D
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y9M14D

Files In Submission

Name View Source Status
0000950170-23-039770-index-headers.html Edgar Link pending
0000950170-23-039770-index.html Edgar Link pending
0000950170-23-039770.txt Edgar Link pending
0000950170-23-039770-xbrl.zip Edgar Link pending
cue-20230630.htm Edgar Link pending
cue-20230630.xsd Edgar Link pending
cue-ex10_1.htm Edgar Link pending
cue-ex10_2.htm Edgar Link pending
cue-ex10_3.htm Edgar Link pending
cue-ex31_1.htm Edgar Link pending
cue-ex31_2.htm Edgar Link pending
cue-ex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img77023932_0.jpg Edgar Link pending
img77023932_1.jpg Edgar Link pending
img77023932_2.jpg Edgar Link pending
img77023932_3.jpg Edgar Link pending
img77023932_4.jpg Edgar Link pending
img77023932_5.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
cue-20230630_cal.xml Edgar Link unprocessable
cue-20230630_def.xml Edgar Link unprocessable
cue-20230630_lab.xml Edgar Link unprocessable
cue-20230630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
cue-20230630_htm.xml Edgar Link completed
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending